Flerie Invest

Flerie Invest is a Stockholm-based investment firm with a dedicated focus on the life sciences sector, encompassing pharmaceuticals, medical technology, and digital health. Founded by Carl-Johan Spak, the firm distinguishes itself through its specialized expertise and a strategic approach to capital deployment within the European healthcare landscape. Operating from Sweden, Flerie Invest is recognized for its commitment to fostering innovation and growth in companies that are developing groundbreaking solutions for global health challenges.

The firm's investment strategy is characterized by a long-term ownership horizon and a preference for taking significant stakes in its portfolio companies. Flerie Invest actively invests in both private and public entities, demonstrating flexibility across different market stages. Their involvement often extends beyond mere capital provision, leveraging their deep industry knowledge and network to support the strategic development and commercialization efforts of their portfolio. This hands-on approach is crucial for the complex and highly regulated life science industry.

Flerie Invest typically targets companies that are beyond the very early stages, often those in clinical development or approaching commercialization, where substantial capital is required to advance products through regulatory pathways and market entry. For instance, the firm participated in a SEK 160 million (approximately $15 million USD) financing round for XNK Therapeutics, highlighting their capacity to contribute to significant capital raises. Furthermore, Flerie Invest demonstrated its leadership by leading a SEK 100 million (approximately $9.5 million USD) financing round for Modus Therapeutics. These examples underscore their capability to deploy multi-million dollar investments, indicative of their commitment to scaling impactful life science ventures. Their typical first check sizes for private companies generally range from $3 million to $15 million, reflecting their focus on later-stage growth and strategic partnerships.